JM-4

JM-4 is an investigational therapeutic agent under development for the treatment of neurodegenerative diseases, particularly tauopathies such as Alzheimer's disease and related dementias. Preclinical studies in PS19 mouse models have shown that daily subcutaneous administration of JM-4 before disease onset reduces neurological deficits, prolongs lifespan, and improves cognitive function. These effects are associated with reductions in neuronal loss, phosphorylated tau aggregation, and microglial activation. Additionally, JM-4 has been studied for its potential benefits in chronic relapsing experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis[1]. The precise molecular mechanism of action is not fully detailed in available sources but appears to involve modulation of neuroinflammation and tau pathology[1].